Circulating tumor cell separating and enriching device on basis of closed loops

Abstract

The invention provides a circulating tumor cell (CTC) separating and enriching device on the basis of closed loops. The circulating tumor cell separating and enriching device is characterized by comprising an acquisition channel, an anticoagulation channel, a control valve, a blood collector, a blood collecting bag, a CTC acquisition filter and a blood transfusion channel; the acquisition channel and the anticoagulation channel are respectively or jointly connected to an input end of the control valve, a switching end of the control valve is connected with an input end of the blood collecting bag, the blood collecting bag is arranged on the blood collector at a blood acquisition phase, an output end of the blood collecting bag is sequentially connected with the CTC acquisition filter and the blood transfusion channel, and an output end of the blood transfusion channel is connected with another switching end of the control valve. Blood acquisition / transfusion circulating procedures can be switched over by means of changing the position of the blood collecting bag relative to the acquisition channel / the blood transfusion channel. The circulating tumor cell separating and enriching device has the advantages that residual liquid can be successfully transfused on the basis that circulating tumor cells can be separated and enriched to the greatest possible extent, accordingly, loss of the liquid can be prevented, and the circulating tumor cells can be repeatedly acquired in a circulating manner.

Description

technical field [0001] The invention relates to a medical and biological separation and enrichment device, in particular to a circulating tumor cell separation and enrichment device. Background technique [0002] Circulating tumor cells (CTCs) refer to tumor cells that enter the blood circulation due to internal and external factors such as invasion, shedding, and surgical operations. The detection of CTC can be effectively used in early diagnosis in vitro, rapid assessment of chemotherapy drugs, individualized treatment including clinical drug screening, detection of drug resistance, and development of new tumor drugs. The number of peripheral blood CTCs has been proven to be a prognostic marker for most tumor patients such as lung cancer, breast cancer, prostate cancer, and gastric cancer, or a predictive indicator for postoperative recurrence (Joosse SA, GorgesTM, Pantel K.: "Biology, detection, and clinical implications of circulating tumor cells.", EMBOMolMed .2014, 14...

AI Technical Summary

Problems solved by technology

However, these methods are extremely limited in the number of CTCs isolated and enriched after drawing 5-10ml of blood each time (generally 0-20 / 7.5ml);

[0004] In addition, in practical applications, the number of CTCs enriched from 5-10ml of blood drawn each time is basically impossible or difficult to complete the needs of CTC culture. For example, if gene sequencing is performed after enriching CTCs, then Complicated single-cell pre-amplification is required, which is expensive, cumbersome, and technically difficult; and if the CTC enrichment amount is increased by repeating the above-mentioned CTC detection experiment, not only the cost is high, but also blood is drawn repeatedly for detection, which will also make the blood Large loss

The above-mentioned defects in the existing CTC separation and enrichment technology limit the clinical application of related CTC detection technology

Images